Navigation Links
Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
Date:12/15/2009

NEW YORK, Dec. 15 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement

http://www.reportlinker.com/p0168104/The-Future-of-Orphan-Diseases-Therapeutics---Market-Forecasts-to-2015-Pipeline-Analysis-and-Reimbursement.html

Summary

The author has released its latest research "The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement" The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global orphan diseases therapeutics market. The report analyzes the markets for orphan diseases therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, and price are forecast until 2015 for the key geographies as well as select therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

The scope of this report includes:

  • Annualized market data for the orphan diseases therapeutics market from 2000 to 2008, forecast forward to 2015
  • Analysis of the leading therapeutic segments. These include Fabry Disease, Pompe Disease and Mucopolysaccharidosis.
  • Analysis of the orphan diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
  • Market characterization of the orphan diseases therapeutics market including market size, annual cost of therapy, and treatment usage patterns
  • Key drivers and barriers that have a significant impact on the market
  • Coverage of pipeline molecules in various phases of drug development
  • Competitive benchmarking of leading companies. The key companies studied in this report are F.Hoffmann-La Roche, Genzyme Corporation, Novartis AG, Celgene Corporation, Orphan Europe, Pfizer Inc, Actelion Pharmaceuticals and Shire Plc.
  • Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global orphan diseases therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to

  • Align product portfolio to the markets with high growth potential
  • Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
  • Develop key strategic initiatives by understanding key focus areas of leading companies
  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

2.1 The Global Orphan Diseases Therapeutics Market is Forecast to Show Increased Growth Due to Increased Approval of Orphan Drugs

2.2 Orphan Drug Licensing is Growing at a Faster Rate Owing to High Market Potential

2.3 High Unmet Needs in the Boosts the R&D Scenario in Orphan Diseases Therapeutics Market

3 Global Orphan Diseases Market: Introduction

3.1 Disease Overview

3.1.1 The United States

3.1.2 Europe

3.1.3 Japan

3.2 GBI Research Report Guidance

3.3 Market Overview

4 Global Orphan Diseases Therapeutics Market: Market Characterization

4.1 Market Forecasts

4.2 Orphan Drugs by Disease Sectors

4.3 Usage Patterns

4.3.1 Diseased Population

4.3.2 Treatment Seeking Population

4.3.3 Diagnosis Population

4.3.4 Prescription Population

4.3.5 Therapeutic Usage Patterns

4.4 Geographical Distribution

4.4.1 Market Drivers

4.4.1.1 Increasing Approvals of Orphan Drugs and Orphan Drug Designations

4.4.1.2 Increase in awareness levels of disease progression and etiology

4.4.1.3 Federal Support for Research and Development of Orphan Drugs

4.4.2 Market Restraints

4.4.2.1 Lack of access to correct diagnosis

4.4.2.2 High cost of the few existing drugs and care

4.4.2.3 Delay in Diagnosis and Misdiagnosis

4.5 Key Market Trends

4.5.1 Increase Federal Funding

4.5.2 Product Pipeline

4.5.3 Regulatory trends - Current Pricing and Reimbursement Scenario

4.5.3.1 Innovative risk-sharing agreements have emerged as tools to provide market access

4.5.3.2 Excessive Pricing of Orphan Drugs by the Pharma Companies Demands Measures for Greater Price Control

4.5.3.3 Pricing and Reimbursement Issues for Orphan Drugs - Excessive Prices of Orphan Drugs Increasing Financial Pressures on Government

4.5.3.4 Exploiting Orphan Drug Act; Maximizing Revenues

4.5.3.5 Ovation's Indocin and Questcor's H.P. Acthar Gel

4.5.3.6 Pricing an Orphan Drug

4.5.3.7 Price Control Measures

4.5.3.8 Global Approach for Orphan Drug Development

4.5.3.9 Introducing Sales Ceiling and Flexible Market Exclusivity

4.5.3.10 Price Revisions

4.5.3.11 GSK's Retrovir (zidovudine)

4.5.3.12 Amgen's Epogen (erythropoietin)

4.5.3.13 Conclusion

5 Global Fabry Disease Therapeutics Market

5.1 Market Overview

5.2 Market Forecasts

5.3 Average Cost of Therapy

5.4 Usage Patterns

5.4.1 Diseased Population

5.4.2 Treatment Seeking Population

5.4.3 Diagnosis Population

5.4.4 Prescription Population

5.4.5 Therapeutic Usage Patterns

5.5 Product Analysis

5.5.1 Fabryzyme

5.5.2 Replagal

5.6 Drug Pipeline Analysis

6 Global Pompe Disease Therapeutics Market

6.1 Market Overview

6.2 Market Forecasts

6.3 Average Cost of Therapy

6.4 Usage Patterns

6.4.1 Diseased Population

6.4.2 Treatment Seeking Population

6.4.3 Diagnosis Population

6.4.4 Prescription Population

6.4.5 Therapeutic Usage Patterns

6.5 Product Analysis

6.5.1 Myozyme

6.5.1.1 Sales of Myozyme

6.6 Pipeline

7 Global Mucopolysaccharidosis VI Disease Therapeutics Market

7.1 Market Overview

7.2 Market Forecasts

7.3 Average Cost of Therapy

7.4 Usage Patterns

7.4.1 Diseased Population

7.4.2 Treatment Seeking Population

7.4.3 Diagnosis Population

7.4.4 Prescription Population

7.4.5 Therapeutic Usage Patterns

7.5 Product Analysis

7.5.1 Naglazyme

7.5.1.1 Sales of Naglazyme

8 The US Orphan Diseases Therapeutics Market

8.1 Market Overview

8.2 Market Forecasts

8.3 Usage Patterns

8.3.1 Diseased Population

8.3.2 Treatment Seeking Population

8.3.3 Diagnosis Population

8.3.4 Prescription Population

8.3.5 Therapeutic Usage Patterns

9 Europe Orphan Diseases Therapeutics Market

9.1 Market Overview

9.2 Market Forecasts

9.3 Usage Patterns

9.3.1 Diseased Population

9.3.2 Treatment Seeking Population

9.3.3 Diagnosis Population

9.3.4 Prescription Population

9.3.5 Therapeutic Usage Patterns

10 Japan Orphan Diseases Therapeutics Market

10.1 Market Overview

10.2 Market Forecasts

10.3 Usage Patterns

10.3.1 Diseased Population

10.3.2 Treatment Seeking Population

10.3.3 Diagnosis Population

10.3.4 Prescription Population

10.3.5 Therapeutic Usage Patterns

11 Global Orphan Diseases Therapeutics Market: Competitive Landscape

11.1 Overview

11.2 Competitor Profiling

11.2.1 Genzyme Corporation

11.2.1.1 Strengths - Broad Product Base and Orphan Drug Status Strengthens Company's positioning

11.2.1.2 Cerezyme

11.2.1.3 Fabrazyme

11.2.2 Celgene Corporation

11.2.2.1 Strengths - Orphan Drugs Driving Revenues in a Competition Free Environment

11.2.3 Actelion Pharmaceuticals

11.2.4 Shire Pharmaceuticals

11.2.5 AstraZeneca

11.2.6 Boehringer Ingelheim

11.2.7 Bristol-Myers Squibb

11.2.8 GlaxoSmithKline (GSK)

11.2.9 Novartis

11.2.10 Pfizer

11.2.11 Eli Lilly

11.2.12 Sanofi Aventis

11.2.13 UCB Pharma

11.2.14 Wyeth

12 Pipeline Analysis

12.1 Autoimmune Disorders

12.1.1 Cellcept

12.1.2 Pirfenidone

12.1.3 Rituxan

12.2 Genetic Disorders

12.2.1 Denufosol tetrasodium inhalation solution(INS37217)

12.2.2 Bronchitol(Mannitol)

12.2.3 Catena (Idebenone)

12.3 Infectious Diseases

12.3.1 XP-28 (xepol)

12.4 Neurology

12.4.1 Cladribine

12.4.2 Clazosentan (Pivlaz®)

12.5 Respiratory Disorders

12.6 Transplantation

12.7 Cardiovascular Disorders

12.7.1 ISIS 301012(Mipomersen sodium)

12.8 Cancer

12.8.1 Avastin

12.8.2 Enzastaurin

12.8.3 Patupilone

12.8.4 Zactima

12.8.5 Genasense

12.8.6 Ipilimumab (MDX-010, MDX-101)

12.9 Blood Cancer

12.10 Skin Cancer

12.11 Other Disorders

13 Global Orphan Diseases Therapeutics Market: Strategic Consolidations

13.1 Mergers and Acquisitions

13.1.1 Genzyme Corp. and Bioenvision, Inc.

13.1.2 ViroPharma and Lev Pharmaceuticals

13.1.3 Biovitrum and Swedish Orphan

13.1.4 Shire plc and Zymenex A/s

13.2 Licensing Agreements

13.2.1 Overview

13.2.2 Drug Discovery & Preclinical

13.2.2.1 DX-88

13.2.2.2 ThermoDox

13.2.3 Phase I

13.2.3.1 Xenazine

13.2.3.2 BL-1040

13.2.3.3 SB1518

13.2.4 Phase II

13.2.4.1 Treanda

13.2.4.2 Onalta

13.2.4.3 ARQ 197

13.2.4.4 TMC-207

13.2.5 Phase III

13.2.5.1 Glufosfamide

13.2.5.2 Allovectin-7

13.2.5.3 Trizytek

13.2.5.4 OrBec

13.2.5.5 Riquent

13.2.5.6 Xiaflex

13.2.5.7 Eurartesim

13.2.5.8 Gabapentin GR

13.2.6 Approved

13.2.6.1 Cyanokit

13.2.6.2 Fomepizole

13.2.6.3 Xenazine

13.2.6.4 fludarabine

13.2.6.5 Curosurf

13.2.6.6 Campath

13.2.6.7 Epoprostenol

13.2.6.8 Somatostatin-UCB

13.2.6.9 Chenix

13.2.6.10 Gliadel

13.2.6.11 Zevalin

13.2.6.12 Desmopressin Acetate

14 Appendix

14.1 Market Definitions

14.2 Key Support Data

14.3 List of Abbreviations

14.4 Research Methodology

14.4.1 Coverage

14.4.2 Secondary Research

14.4.3 Primary Research

14.4.4 Models

14.4.5 Forecasts

14.4.6 Expert Panels

14.5 Contact Us

14.6 Disclaimer

Table 1: Orphan Diseases Therapeutics Market: Definition and Incentives for Orphan Drugs, 2008

Table 2: Orphan Diseases Therapeutics Market: Orphan Diseases Prevalence, Europe, 2008

Table 3: Orphan Diseases Therapeutics Market, Global, Revenue Forecasts, 2000-2008

Table 4: Orphan Diseases Therapeutics Market, Global, Revenue Forecasts, 2008-2015

Table 5: Orphan Diseases Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2008

Table 6: Orphan Diseases Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015

Table 7: Orphan Diseases Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2008

Table 8: Orphan Diseases Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015

Table 9: Orphan Diseases Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2008

Table 10: Orphan Diseases Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015

Table 11: Orphan Diseases Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2008

Table 12: Orphan Diseases Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015

Table 13: Orphan Diseases Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2008

Table 14: Orphan Diseases Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2008-2015

Table 15: Orphan Diseases Therapeutics Market, Global, Market Drivers, 2009-2015

Figure 14: Orphan Diseases Therapeutics Market, Europe, Approved Orphan Drugs and Indications, 2008

Table 16: Orphan Diseases Therapeutics Market, Global, Market Restraints, 2009 - 2015

Table 17: Orphan Diseases Therapeutics Market, Definition and Incentives for Orphan Drugs, 2008

Figure 17: Orphan Diseases Therapeutics Market, Global, Prevalence and the Annual Cost of Therapy

Table 18: Fabry Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2008

Table 19: Fabry Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2008-2015

Table 20: Fabry Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2001-2008

Table 21: Fabry Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2008-2015

Table 22: Fabry Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2008

Table 23: Fabry Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015

Table 24: Fabry Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2008

Table 25: Fabry Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015

Table 26: Fabry Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2008

Table 27: Fabry Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015

Table 28: Fabry Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2001-2008

Table 29: Fabry Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015

Table 30: Fabry Disease Therapeutics Market, Global, Major Manufacturers and Drugs, 2008

Table 31: Pompe Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2005-2008

Table 32: Pompe Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2005-2015

Table 33: Pompe Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2008

Table 34: Pompe Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015

Table 35: Pompe Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2008

Table 36: Pompe Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015

Table 37: Pompe Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2008

Table 38: Pompe Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015

Table 39: Pompe Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2005-2015

Table 40: Pompe Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2008

Table 41: Pompe Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2008-2015

Table 42: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Major Manufacturers and Drugs, 2008

Table 43: Pompe Disease Therapeutics Market, Global, Myozyme Sales, 2008

Table 44: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2005-2015

Table 45: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2005-2015

Table 46: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2008

Table 47: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015

Table 48: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2008

Table 49: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015

Table 50: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2008

Table 51: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015

Table 52: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2005-2015

Table 53: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Major Manufacturers and Drugs, 2008

Table 54: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Naglazyme Sales, 2008

Table 55: Orphan Diseases Therapeutics Market, The US, Revenue Forecasts ($m), 2000-2008

Table 56: Orphan Diseases Therapeutics Market, The US, Revenue Forecasts ($m), 2008-2015

Table 57: Orphan Diseases Therapeutics Market, The US, Forecasts for Diseased Population, 2000-2008

Table 58: Orphan Diseases Therapeutics Market, The US, Forecasts for Diseased Population, 2008-2015

Table 59: Orphan Diseases Therapeutics Market, The US, Forecasts for Treatment Seeking Population, 2000-2008

Table 60: Orphan Diseases Therapeutics Market, The US, Forecasts for Treatment Seeking Population, 2008-2015

Table 61: Orphan Diseases Therapeutics Market, The US, Forecasts for Diagnosis Population, 2000-2008

Table 62: Orphan Diseases Therapeutics Market, The US, Forecasts for Diagnosis Population, 2008-2015

Table 63: Orphan Diseases Therapeutics Market, The US, Forecasts for Prescription Population, 2000-2008

Table 64: Orphan Diseases Therapeutics Market, The US, Forecasts for Prescription Population, 2008-2015

Table 65: Orphan Diseases Therapeutics Market, The US, Forecasts for Therapeutic Usage Patterns, 2000-2008

Table 66: Orphan Diseases Therapeutics Market, The US, Forecasts for Therapeutic Usage Patterns, 2008-2015

Table 67: Orphan Diseases Therapeutics Market, Europe, Revenue Forecasts ($bn), 2000-2008

Table 68: Orphan Diseases Therapeutics Market, Global, Revenue Forecasts ($bn), 2008-2015

Table 69: Orphan Diseases Therapeutics Market, Europe, Forecasts for Diseased Population, 2000-2008

Table 70: Orphan Diseases Therapeutics Market, Europe, Forecasts for Diseased Population, 2008-2015

Table 71: Orphan Diseases Therapeutics Market, Europe, Forecasts for Treatment Seeking Population, 2000-2008

Table 72: Orphan Diseases Therapeutics Market, Europe, Forecasts for Treatment Seeking Population, 2008-2015

Table 73: Orphan Diseases Therapeutics Market, Europe, Forecasts for Diagnosis Population, 2000-2008

Table 74: Orphan Diseases Therapeutics Market, Europe, Forecasts for Diagnosis Population, 2008-2015

Table 75: Orphan Diseases Therapeutics Market, Europe, Forecasts for Prescription Population, 2000-2008

Table 76: Orphan Diseases Therapeutics Market, Europe, Forecasts for Prescription Population, 2008-2015

Table 77: Orphan Therapeutics Market, Europe, Forecasts for Therapeutic Usage Patterns, 2000-2015

Table 78: Orphan Therapeutics Market, Europe, Forecasts for Therapeutic Usage Patterns, 2000-2015

Table 79: Orphan Diseases Therapeutics Market, Japan, Revenue Forecasts ($m), 2000-2015

Table 80: Orphan Diseases Therapeutics Market, Japan, Revenue Forecasts ($m), 2002-2015

Table 81: Orphan Diseases Therapeutics Market, Japan, Forecasts for Diseased Population, 2000-2008

Table 82: Orphan Diseases Therapeutics Market, Japan, Forecasts for Diseased Population, 2008-2015

Table 83: Orphan Diseases Therapeutics Market, Japan, Forecasts for Treatment Seeking Population, 2000-2008

Table 84: Orphan Diseases Therapeutics Market, Japan, Forecasts for Treatment Seeking Population, 2008-2015

Table 85: Orphan Diseases Therapeutics Market, Japan, Forecasts for Diagnosis Population, 2000-2008

Table 86: Orphan Diseases Therapeutics Market, Japan, Forecasts for Diagnosis Population, 2008-2015

Table 87: Orphan Diseases Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2008

Table 88: Orphan Diseases Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015

Table 89: Orphan Diseases Therapeutics Market, Japan, Forecasts for Therapeutic Usage Patterns, 2000-2008

Table 90: Orphan Diseases Therapeutics Market, Japan, Forecasts for Therapeutic Usage Patterns, 2008-2015

Table 91: Orphan Diseases Therapeutics Market, Global, Pipeline Analysis of Autoimmune Disorders, 2008

Table 92: Orphan Diseases Therapeutics Market, Global, Pipeline Analysis of Genetic Disorders, 2008

Table 93: Orphan Diseases Therapeutics Market, Global, Pipeline Analysis of Infectious Diseases, 2008

Table 94: Orphan Diseases Therapeutics Market, Global, Pipeline Analysis of Neurology Disorders, 2008

Table 95: Orphan Diseases Therapeutics Market, Global, Pipeline Analysis of Respiratory Disorders, 2008

Table 96: Orphan Diseases Therapeutics Market, Global, Pipeline Analysis of Transplantation, 2008

Table 97: Orphan Diseases Therapeutics Market, Global, Pipeline Analysis of Cardiovascular Disorders, 2008

Table 98: Orphan Diseases Therapeutics Market, Global, Pipeline Analysis of Cancer, 2008

Table 99: Orphan Diseases Therapeutics Market, Global, Pipeline Analysis of Blood Cancer, 2008

Table 100: Orphan Diseases Therapeutics Market, Global, Pipeline Analysis of Skin Cancer, 2008

Table 101: Orphan Diseases Therapeutics Market, Global, Pipeline Analysis of Autoimmune Disorders, 2008

Table 102: Orphan Diseases Therapeutics Market, Global, Licensing Agreements for Drugs in the Discovery and Preclinical Stages, 2008

Table 103: Orphan Diseases Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase I Stage, 2008

Table 104: Orphan Diseases Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase II Stages, 2008

Table 105: Orphan Diseases Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase III Stages, 2008

Table 106: Orphan Diseases Therapeutics Market, Global, Licensing Agreements for Drugs in the Approved Stages, 2008

List of Figures

Figure 1: Orphan Diseases Therapeutics Market, Global, Market Overview, 2008

Figure 2: Orphan Diseases Therapeutics Market, Global, Revenue Forecasts, 2000-2015

Figure 3: Orphan Diseases Therapeutics Market, The US, Orphan Drugs by Disease Sectors, 2008

Figure 4: Orphan Diseases Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015

Figure 5: Orphan Diseases Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2015

Figure 6: Orphan Diseases Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2015

Figure 7: Orphan Diseases Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2015

Figure 8: Orphan Diseases Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2015

Figure 9: Orphan Diseases Therapeutics Market, Global, Geographical Distribution of Revenues ($bn), 2000-2015

Figure 10: Orphan Diseases Therapeutics Market, Global, Geographical Comparison of Market Competition, 2008

Figure 11: Orphan Diseases Therapeutics Market, Global, Market Indicators, 2008

Figure 12: Orphan Diseases Therapeutics Market, The US, Approved Orphan Drugs, 20008-2009

Figure 13: Orphan Diseases Therapeutics Market, The US and Europe, Designated Orphan Drugs, 2004-2018

Figure 14: Orphan Diseases Therapeutics Market, Europe, Approved Orphan Drugs and Indications, 2008

Figure 15: Orphan Diseases Therapeutics Market, Global, Key Market Events, 2008-2015

Figure 16: Orphan Diseases Therapeutics Market, Global, Pricing of an Orphan Drug, 2008

Figure 17: Orphan Diseases Therapeutics Market, Global, Prevalence and the Annual Cost of Therapy

Figure 18: Orphan Diseases Therapeutics Market, Global, Price Control Measures on Orphan Drugs

Figure 19: Fabry Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2015

Figure 20: Fabry Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2001-2015

Figure 21: Fabry Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015

Figure 22: Fabry Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2015

Figure 23: Fabry Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2015

Figure 24: Fabry Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2015

Figure 25: Fabry Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2015

Figure 26: Fabry Disease Therapeutics Market, Global, Market Share of Major Therapeutic Drugs, 2008

Figure 27: Fabry Disease Therapeutics Market, Global, Historical Revenues of Major Drugs ($m), 2006-2008

Figure 28: Pompe Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2005-2015

Figure 29: Pompe Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2005-2015

Figure 30: Pompe Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015

Figure 31: Pompe Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2015

Figure 32: Pompe Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2015

Figure 33: Pompe Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2005-2015

Figure 34: Pompe Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2015

Figure 35: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2005-2015

Figure 36: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2005-2015

Figure 37: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015

Figure 38: Fabry Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2015

Figure 39: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2015

Figure 40: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2005-2015

Figure 41: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2015

Figure 42: Orphan Diseases Therapeutics Market, The US, Revenue Forecasts ($m), 2000-2015

Figure 43: Orphan Diseases Therapeutics Market, The US, Forecasts for Diseased Population, 2000-2015

Figure 44: Orphan Diseases Therapeutics Market, The US, Forecasts for Treatment Seeking Population, 2000-2015

Figure 45: Orphan Diseases Therapeutics Market, The US, Forecasts for Diagnosis Population, 2000-2015

Figure 46: Orphan Diseases Therapeutics Market, The US, Forecasts for Prescription Population, 2000-2015

Figure 47: Orphan Diseases Therapeutics Market, The US, Forecasts for Therapeutic Usage Patterns, 2000-2015

Figure 48: Orphan Diseases Therapeutics Market, Europe, Revenue Forecasts ($bn), 2000-2015

Figure 49: Orphan Diseases Therapeutics Market, Europe, Forecasts for Diseased Population, 2000-2015

Figure 50: Orphan Diseases Therapeutics Market, Europe, Forecasts for Treatment Seeking Population, 2000-2015

Figure 51: Orphan Diseases Therapeutics Market, Europe, Forecasts for Diagnosis Population, 2000-2015

Figure 52: Orphan Diseases Therapeutics Market, Europe, Forecasts for Prescription Population, 2000-2015

Figure 53: Orphan Therapeutics Market, Europe, Forecasts for Therapeutic Usage Patterns, 2000-2015

Figure 54: Orphan Diseases Therapeutics Market, Japan, Revenue Forecasts ($m), 2000-2015

Figure 55: Orphan Diseases Therapeutics Market, Japan, Forecasts for Diseased Population, 2000-2015

Figure 56: Orphan Diseases Therapeutics Market, Japan, Forecasts for Treatment Seeking Population, 2000-2015

Figure 57: Orphan Disease Therapeutics Market, Japan, Forecasts for Diagnosis Population, 2000-2015

Figure 58: Orphan Diseases Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2015

Figure 59: Orphan Diseases Therapeutics Market, Japan, Forecasts for Therapeutic Usage Patterns, 2000-2015

Figure 60: Orphan Diseases Therapeutics Market, The US, Orphan Drug Indications, 2000-2008

Figure 61: Orphan Diseases Therapeutics Market, Global, Sales Revenues of Orphan Drugs, 2008

Figure 62: Orphan Diseases Therapeutics Market, Global, Pipeline Split by Disease Sectors, 2008

Figure 63: Orphan Diseases Therapeutics Market, Global, Licensing Agreements Split by Disease Sectors, 2008

Figure 64: Orphan Diseases Therapeutics Market, Global, Licensing Agreements Split by Clinical Trial Phase, 2008

Figure 65: Orphan Diseases Therapeutics Market, Global, Licensing Agreements Split by Deal Size, 2008

Figure 66: GBI Research Methodology

Companies mentioned

Genzyme Corporation

Celgene Corporation

Actelion Pharmaceuticals

Shire Pharmaceuticals

AstraZeneca

Boehringer Ingelheim

Bristol-Myers Squibb

GlaxoSmithKline (GSK)

Novartis

Eli Lilly

Sanofi Aventis

UCB Pharma

To order this report:

Pharmaceutical Industry: The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement

More Market Research Report


    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved


Related biology technology :

1. Reportlinker Adds Biotechnology Instrumentation - International Market Trends
2. Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective
3. Reportlinker Adds Pharmacodynamic Assays
4. Reportlinker Adds Neurostimulation - A Global Market Perspective
5. Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective
6. Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities
7. Reportlinker Adds Chromium - Global Market Trends
8. Reportlinker Adds Industrial Enzymes - A Global Market Report
9. Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment
10. Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013
11. Reportlinker Adds Biotechnology Reagents - A Global Market Perspective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... SAN DIEGO , Feb. 12, 2016 Biocom, ... life science community, took a group of San ... as part of its 2016 Precision Medicine Advocacy Fly-In. ... at the Food and Drug Administration (FDA), the Centers for ... (NIH), as well as San Diego U.S. Representatives Susan ...
(Date:2/11/2016)... , February 11, 2016 Non-profit Consortium ... Genetic Understanding to Support Research and Discovery ... today announced an ambitious plan to sequence 100,000 individuals. It ... countries and at least 7 of North and East Asian ... the first phase, the project will focus on creating phased ...
(Date:2/11/2016)... 2016  Spectra BioPharma Selling Solutions (Spectra) is ... biopharma companies the experience, expertise, operational delivery and ... sales teams. Created in concert with industry leading ... strategic and tactical needs of its clients by ... both personal and non-personal promotion. ...
(Date:2/11/2016)...   BioInformant announces the February 2016 release ... Opportunities, Tools, and Technologies – Market Size, Segments, Trends, ... The first and only market ... BioInformant has more than a decade of historical information ... stem cell type. This powerful 175 page global strategic ...
Breaking Biology Technology:
(Date:2/3/2016)... , February 4, 2016 --> ... SEK 1,351.5 M (105.0), up 1,187% compared with fourth quarter of 2014. ... to SEK 517.6 M (loss: 30.0). Earnings per share increased ... was SEK 537.4 M (neg: 74.7). , ... Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% compared with 2014. ...
(Date:2/3/2016)... , Feb. 3, 2016 Vigilant Solutions announces ... Department in Missouri solved two ... reader (LPR) data from Vigilant Solutions. Brian ... in which the victim was walking out of a convenience store and witnessed ... next to his vehicle, striking his vehicle and leaving ...
(Date:2/2/2016)... Feb. 2, 2016  BioMEMS devices deployed ... focused on medical screening and diagnostic applications, ... Wearable devices that facilitate and assure continuous ... movement are being bolstered through new opportunities ... signal acquisition coupled with wireless connectivity and ...
Breaking Biology News(10 mins):